Age, median (IQR), years
|
63.5 (51–76)
|
58 (44–68)
|
1.02
|
1.00-1.04
|
0.019
|
1.01
|
0.99-1.03
|
0.305
|
Female
|
44 (38)
|
53 (46)
|
0.74
|
0.44-1.23
|
0.243
| | | |
Transfer from another hospital
|
21 (18)
|
14 (12)
|
1.64
|
0.77-3.46
|
0.198
| | | |
Unit of admission
| | | | | | | | |
Non-haematology/oncology to read Non-haematology/oncology
|
73 (63)
|
49 (42)
|
Reference
|
Reference
|
Haematology/oncology
|
43 (37)
|
67 (58)
|
0.04
|
0.01-0.30
|
0.002
|
0.08
|
0.01-0.74
|
0.026
|
ICU admission in prior 30 days
|
29 (25)
|
13 (11)
|
2.60
|
1.25-5.39
|
0.010
|
1.71
|
0.52-5.58
|
0.373
|
CDS-VRE score, median (IQR)
|
0 (0–1)
|
0 (0–1.6)
|
0.89
|
0.66-1.20
|
0.446
| | | |
Clostridium difficile toxin positive
|
2 (2)
|
1 (1)
|
2.00
|
0.18-22.06
|
0.571
| | | |
Infection(s) due to pathogens other than Enterococci
|
43 (37)
|
34 (29)
|
1.45
|
0.82-2.56
|
0.201
| | | |
Gastrointestinal disease
|
64 (55)
|
38 (33)
|
3.00
|
1.60-5.62
|
0.001
|
2.29
|
1.05-4.99
|
0.037
|
Liver disease
|
13 (11)
|
15 (13)
|
0.71
|
0.23-2.25
|
0.566
| | | |
Haematological malignancy
|
35 (30)
|
63 (54)
|
0.15
|
0.06-0.39
|
<0.001
|
0.40
|
0.12-1.33
|
0.134
|
Bone marrow transplantation type
|
Nil
|
105 (91)
|
100 (86)
| |
Reference
|
Reference
|
Autologous
|
2 (2)
|
7 (6)
|
0.29
|
0.06-1.38
|
0.118
| | | |
Allogeneic
|
9 (8)
|
9 (8)
|
1.00
|
0.38-2.66
|
1.000
| | | |
Ceftriaxone days, median (IQR), days
|
0 (0–0.5)
|
0 (0)
|
1.10
|
0.99-1.24
|
0.088
| | | |
Third generation cephalosporin days , median (IQR), daysa
|
0 (0–1)
|
0 (0–0.49)
|
1.03
|
0.94-1.13
|
0.523
| | | |
Fluoroquinolone days, median (IQR), daysb
|
0 (0–1.04)
|
0 (0–2.42)
|
0.96
|
0.91-1.02
|
0.190
| | | |
Metronidazole days, median (IQR), days
|
0 (0)
|
0 (0)
|
1.23
|
1.06-1.43
|
0.007
|
1.23
|
1.02-1.48
|
0.032
|
Ticarcillin-clavulanic acid days, median (IQR), days
|
0 (0)
|
0 (0)
|
1.02
|
0.93-1.11
|
0.711
| | | |
Piperacillin-tazobactam days, median (IQR), days
|
0 (0)
|
0 (0)
|
0.89
|
0.79-1.00
|
0.054
| | | |
Meropenem days, median (IQR), days
|
0 (0)
|
0 (0)
|
1.00
|
0.92-1.08
|
0.934
| | | |
Vancomycin days, median (IQR), days
|
0 (0–1.25)
|
0 (0–2.18)
|
0.97
|
0.92-1.03
|
0.343
| | | |
Neutropenia days, median (IQR), days
|
0
|
0 (0–1)
|
0.98
|
0.94-1.02
|
0.344
|
1.00
|
0.94-1.06
|
0.911
|
Hypoalbuminaemia days, median (IQR), days
|
7 (1–16)
|
5 (1–13.5)
|
1.01
|
0.98-1.05
|
0.479
|
1.00
|
0.95-1.05
|
0.888
|
Central line use
|
59 (51)
|
55 (47)
|
1.17
|
0.67-2.05
|
0.572
| | | |
Mechanical ventilation
|
17 (15)
|
7 (6)
|
2.67
|
1.04-6.81
|
0.040
| | | |
Urinary catheter
|
46 (40)
|
27 (23)
|
2.12
|
1.19-3.77
|
0.011
|
1.16
|
0.47-2.88
|
0.741
|
Parenteral nutrition
|
16 (14)
|
8 (7)
|
2.00
|
0.86-4.67
|
0.109
| | | |